Abstract:STUDY QUESTION:Is phosphatase of regenerating liver-3 (PRL-3) associated with increased motility of endometriotic cells from endometrioma?SUMMARY ANSWER:Elevated PRL-3 promotes cytoskeleton reorganization, cell migration and invasion of endometrial stromal cells (ESCs) from endometrioma.WHAT IS KNOWN ALREADY:Overexpression of PRL-3 is associated with cancer cell migration, invasion and metastatic phenotype.STUDY DESIGN, SIZE, DURATION:Primary human ESCs were isolated from eutopic endometrium of women without endometriosis (EuCo, n = 10), with histologically proven endometrioma (EuEM, n = 19) and from the cyst wall of ovarian endometriosis (OvEM, n = 26).PARTICIPANTS/MATERIALS, SETTING, METHODS:The expression of PRL-3 in ESCs derived from EuCo, EuEM and OvEM at different phases of menstrual cycle were compared. The protein and mRNA levels of PRL-3 were examined by western blot and RT-qPCR, respectively. ESCs from OvEM were transfected with/without short hairpin RNA (shRNA) or small interfering RNA (siRNA). Additionally, a plasmid-mediated delivery system was used to achieve PRL-3 overexpression in ESCs from EuEM. The cellular distribution of F-actin and α-tubulin were examined by immunocytochemistry. Cell motility was evaluated by a transwell migration/invasion assay.MAIN RESULTS AND THE ROLE OF CHANCE:The protein and mRNA levels of PRL-3 are significantly elevated in ESCs from OvEM compared with EuCo and EuEM. The expression of PRL-3 was not altered between proliferative phase and secretory phase in ESCs from all groups. Knockdown of PRL-3 significantly modified the distribution of F-actin and α-tubulin cytoskeleton, inhibited cell migration and invasion. Endogenous inhibition of PRL-3 attenuated the expression of Ras homolog gene family members A and C (RhoA, RhoC), Rho-associated coiled-coil-containing protein kinase 1 (ROCK1) and matrix metalloproteinase (MMP) 9, but not MMP2 in ESCs from OvEM. Additionally, overexpression of PRL-3 in ESCs from EuEM up-regulates cell migration and invasion, and increases the expression of RhoA, RhoC, ROCK1 and MMP9.LIMITATIONS, REASONS FOR CAUTION:Lack of in vivo animal studies is the major limitation of our report. Our results should be further confirmed in a larger cohort of patients and extended to include eutopic and ectopic endometrium from patients with peritoneal endometriosis at different stages of the disease.WIDER IMPLICATIONS OF THE FINDINGS:Our study describes that elevated expression of PRL-3 contributes to the cell motility of ESCs from endometrioma. The results emphasize the importance of metastatic-related factor PRL-3 in the pathogenesis of endometrioma.STUDY FUNDING/COMPETING INTEREST:This work was supported by National Natural Science Foundation of China (No. 81170546) and Zhejiang Medicine Science and Technology Projects (No. Y13H040003). The authors declare no conflict of interest.

NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer

NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency

NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression

NLRC5 promotes tumorigenesis by regulating the PI3K/AKT signaling pathway in cervical cancer

NLRC5 exerts anti-endometriosis effects through inhibiting ERβ-mediated inflammatory response

NLRC5 Inhibits Inflammation of Secretory Phase Ectopic Endometrial Stromal Cells by Up-Regulating Autophagy in Ovarian Endometriosis

LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer

NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer

Long Noncoding RNA LSINCT5 Promotes Endometrial Carcinoma Cell Proliferation, Cycle, and Invasion by Promoting the Wnt/β-catenin Signaling Pathway Via HMGA2

NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in endometrial cancer

Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer

Long Non-Coding RNA NNT-AS1 Positively Regulates NPM1 Expression to Affect the Proliferation of Estrogen-Mediated Endometrial Carcinoma by Interacting

Elevated Phosphatase of Regenerating Liver 3 (Prl-3) Promotes Cytoskeleton Reorganization, Cell Migration and Invasion in Ectopic Stromal Cells from Endometrioma

LncRNA NEAT1 Promotes Endometrial Cancer Cell Proliferation, Migration and Invasion by Regulating the Mir-144-3p/ezh2 Axis

Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes

LncRNA RP11-395G23.3 Suppresses the Endometrial Cancer Progression Via Regulating Microrna-205-5p/pten Axis.

lncRNA OIP5-AS1 Suppresses Cell Proliferation and Invasion of Endometrial Cancer by Regulating PTEN/AKT via Sponging miR-200c-3p

CCL20 Mediates RANK/RANKL-induced Epithelial-Mesenchymal Transition in Endometrial Cancer Cells.

Lnc-Na Inhibits Proliferation And Metastasis In Endometrioid Endometrial Carcinoma Through Regulation Of Nr4a1

The mechanism of L1 cell adhesion molecule interacting with protein tyrosine kinase 2 to regulate the focal adhesion kinase–growth factor receptor-bound protein 2–son of sevenless–rat sarcoma pathway in the identification and treatment of type I high-risk endometrial cancer

NLRP3 inflammasome activation by estrogen promotes the progression of human endometrial cancer